Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
Auro Laboratories Ltd (530233)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530233 NSE: Pharmaceuticals & Drugs | Small Cap | Auro Laboratories Share Price
₹243.90 0.00 (0.00%)
As on 24-Jul'26 16:59
Auro Laboratories Ltd (530233)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530233 NSE: Pharmaceuticals & Drugs | Small Cap | Auro Laboratories Share Price
₹243.90 0.00 (0.00%)
As on 24-Jul'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹152 Cr.
Current Price
₹243.9
52-Week Low / High
₹159 / 317
TTM EPS
₹5.7
TTM Sales
₹30.7 Cr.
Book Value per Share
₹74.4
P/E Ratio
43.03
Higher than its 5-year historical median
Industry PE
52.9
Price to Book (P/B)
3.28
Higher than its 5-year historical median
Price to Sales (P/S)
4.95
Higher than its 5-year historical median
EV/EBITDA
17.78
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
7.91%
Underperforms industry median
Return on Capital Employed (ROCE)
9.17%
Underperforms industry median
Return on Assets (ROA)
3.21%
Operating Profit Margin
33.2%
Net Profit Margin
11.49%
Gross Profit Margin
25.3%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
60.77%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
219.81%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
91.85%
Asset Quality
Promoter Holding
52.40%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹40 Cr.
Equity
₹6.2 Cr.
Face Value
₹10
All Time Low / High
₹0.70 / 317.00
Check Before You Invest
Quality
Somewhat GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Auro Laboratories Ltd a good quality company?
Auro Laboratories Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Auro Laboratories Ltd performance compare with that of its Peers?
Revenue growth of Auro Laboratories Ltd vs industry peers?
Auro Laboratories Ltd revenue CAGR is -10.74%, compared to the industry median CAGR of 5.34%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Auro Laboratories Ltd?
Promoters hold 52.40% of the Auro Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Auro Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 24.5% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Auro Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 20.2% | 28.7% | 29.1% | 24.8% | 38.9% | 12.2% | 9.9% | 20.4% | 3.8% | 9.2% | - |
| Value Creation Index ⓘ | 0.5 | 1.1 | 1.1 | 0.8 | 1.8 | -0.1 | -0.3 | 0.5 | -0.7 | -0.4 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 35.5 | 40.8 | 46.8 | 43.8 | 54.3 | 50.9 | 52.9 | 53.6 | 19.1 | 30.7 | 31 |
| Sales YoY Gr. | - | 15% | 14.8% | -6.5% | 23.9% | -6.2% | 4% | 1.4% | -64.4% | 60.8% | - |
| Adj EPS ⓘ | 0.8 | 5.2 | 6.1 | 5.5 | 10.9 | 3.7 | 3 | 10.9 | 2.3 | 4.5 | 5.7 |
| YoY Gr. | - | 561.5% | 18% | -9% | 96.2% | -65.7% | -20.1% | 265.4% | -78.9% | 95.2% | - |
| BVPS (₹) ⓘ | 15.1 | 20.8 | 27.9 | 34.5 | 45.9 | 50.6 | 54.9 | 67.3 | 68.9 | 74.4 | 74.4 |
| Adj Net Profit ⓘ | 0.5 | 3.2 | 3.8 | 3.5 | 6.8 | 2.3 | 1.9 | 6.8 | 1.4 | 2.8 | 4 |
| Cash Flow from Ops. ⓘ | 5.9 | 4.8 | 6.9 | 9.3 | 12.8 | -6.6 | 3.3 | 18.8 | 5 | 2.1 | - |
| Debt/CF from Ops. ⓘ | 1.7 | 1.9 | 1.2 | 0.3 | 0.3 | -2.1 | 2 | 1.4 | 9 | 30 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -1.6% | -10.7% | -16.6% | 60.8% | ||||
| Adj EPS ⓘ | 21.5% | -16.2% | 14.6% | 95.2% | ||||
| BVPSⓘ | 19.4% | 10.2% | 10.7% | 7.9% | ||||
| Share Price | 25.6% | 6.8% | 42.3% | -10.2% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 5.4 | 28.7 | 25 | 17.7 | 27.1 | 7.7 | 5.7 | 17.8 | 3.4 | 6.3 | 7.6 |
| Op. Profit Mgn % ⓘ | 12.5 | 15.6 | 14.9 | 14.3 | 20.7 | 9.1 | 8.3 | 19.9 | 16.4 | 33.2 | 31.7 |
| Net Profit Mgn % ⓘ | 1.4 | 7.9 | 8.1 | 7.9 | 12.5 | 4.6 | 3.5 | 12.7 | 7.5 | 9.1 | 11.5 |
| Debt to Equity ⓘ | 1.1 | 0.7 | 0.5 | 0.2 | 0.1 | 0.4 | 0.2 | 0.6 | 1.1 | 1.4 | 0 |
| Working Cap Days ⓘ | 124 | 119 | 112 | 112 | 87 | 139 | 202 | 212 | 478 | 301 | 115 |
| Cash Conv. Cycle ⓘ | 39 | 29 | 37 | 39 | 20 | 58 | 84 | 81 | 113 | 142 | -23 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35 | 41 | 47 | 44 | 54 | 51 | 53 | 54 | 19 | 31 |
| Operating Expenses ⓘ + | 31 | 34 | 40 | 38 | 43 | 46 | 49 | 43 | 16 | 21 |
| Operating Profit ⓘ | 4 | 6 | 7 | 6 | 11 | 5 | 4 | 11 | 3 | 10 |
| Operating Profit Margin (%) | 12.5% | 15.6% | 14.9% | 14.3% | 20.7% | 9.1% | 8.3% | 19.9% | 16.4% | 32.6% |
| Other Income ⓘ + | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 |
| Interest ⓘ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 4 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| Profit Before Tax ⓘ | 3 | 5 | 6 | 6 | 11 | 4 | 3 | 10 | 2 | 5 |
| Tax ⓘ | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 3 | 0 | 1 |
| Profit After Tax | 1 | 4 | 4 | 4 | 7 | 3 | 2 | 8 | 2 | 4 |
| PAT Margin (%) | 2.3% | 8.7% | 9.4% | 9.3% | 13.2% | 5.6% | 4.6% | 14.5% | 9.6% | 11.5% |
| Adjusted EPS (₹) | 1.3 | 5.7 | 7.1 | 6.5 | 11.5 | 4.6 | 3.9 | 12.5 | 3.0 | 5.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Valuation of Auro Laboratories - Standalone
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 9 | 13 | 17 | 21 | 29 | 32 | 34 | 42 | 43 | 46 | |
| Debt + | 10 | 9 | 8 | 3 | 3 | 13 | 6 | 26 | 43 | 61 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 5 | 5 | 5 | 5 | 6 | 5 | 11 | 6 | 6 | 5 | |
| Others Liabilities ⓘ | 3 | 3 | 3 | 3 | 5 | 5 | 4 | 11 | 6 | 9 | |
| Total Liabilities ⓘ | 27 | 30 | 33 | 32 | 42 | 55 | 56 | 86 | 99 | 121 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 13 | 13 | 15 | 14 | 14 | 14 | 13 | 22 | 21 | 75 | |
| CWIP ⓘ | 0 | 1 | 0 | 0 | 0 | 4 | 8 | 33 | 56 | 14 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 1 | 1 | 3 | 4 | 3 | 4 | 12 | 8 | 4 | 14 | |
| Trade Receivables | 8 | 8 | 9 | 6 | 7 | 14 | 12 | 13 | 9 | 9 | |
| Cash Equivalents | 1 | 2 | 4 | 6 | 15 | 12 | 2 | 2 | 1 | 2 | |
| Others Assets ⓘ | 4 | 4 | 3 | 2 | 4 | 7 | 9 | 8 | 8 | 7 | |
| Total Assets ⓘ | 27 | 30 | 33 | 32 | 42 | 55 | 56 | 86 | 99 | 121 | |
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 6 | 5 | 7 | 9 | 13 | -7 | 3 | 19 | 5 | 2 |
| Cash Flow From Investing Activity ⓘ + | -2 | -2 | -3 | -2 | -4 | -5 | -5 | -39 | -24 | -15 |
| Cash Flow From Financing Activity ⓘ + | -4 | -2 | -2 | -6 | -0 | 10 | -8 | 19 | 18 | 14 |
| Net Cash Flow ⓘ | 0 | 1 | 2 | 2 | 9 | -2 | -10 | -1 | -1 | 1 |
Financial Ratio
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 9.06 | 31.53 | 28.95 | 20.84 | 28.67 | 9.47 | 7.43 | 20.46 | 4.33 | 7.91 |
| ROCE (%) | 20.24 | 28.65 | 29.12 | 24.8 | 38.88 | 12.2 | 9.92 | 20.37 | 3.79 | 9.17 |
| Asset Turnover Ratio | 1.41 | 1.43 | 1.47 | 1.33 | 1.46 | 1.05 | 0.95 | 0.76 | 0.21 | 0.28 |
| PAT to CFO Conversion(x) | 6 | 1.25 | 1.75 | 2.25 | 1.86 | -2.33 | 1.5 | 2.38 | 2.5 | 0.5 |
| Working Capital Days | ||||||||||
| Receivable Days | 62.80 | 71.90 | 65.80 | 59.50 | 44 | 75 | 89.80 | 87.80 | 217.50 | 110.10 |
| Inventory Days | 27.80 | 12.60 | 19 | 31 | 22.20 | 24.40 | 55.20 | 68 | 113.60 | 102.20 |
| Payable Days | 69.30 | 75.50 | 66.90 | 74 | 67.10 | 59.10 | 83.60 | 121.50 | 246.20 | 327.90 |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Auro Laboratories Ltd FAQs
The current trading price of Auro Laboratories on 24-Jul-2026 16:59 is ₹243.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Jul-2026 the market cap of Auro Laboratories stood at ₹152.0 Cr
The latest P/E ratio of Auro Laboratories as of 23-Jul-2026 is 43.03.
The latest P/B ratio of Auro Laboratories as of 23-Jul-2026 is 3.28.
The 52-week high of Auro Laboratories is ₹317.0 and the 52-week low is ₹159.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Auro Laboratories is ₹30.74 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Auro Laboratories Ltd is a average quality company.
The key valuation ratios of Auro Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Auro Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Auro Laboratories Ltd
Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah.
Company’s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on 14th July, 1992. The manufacturing facility has an installed capacity in excess of 500 tonnes per annum.
Company is primarily focused on manufacturing anti-diabetic drugs. Presently company caters its products in therapeutic segment such as antihistamine, anti-fungal, anti-ulcer, anti-malaria, anti-inflammatory, antacids and others. Company exports its products in countries like Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. Auro Laboratories received ISO 9001:2000 and WHO - cGMP certifications for its quality management.
Products
APIs- Under this company manufactures drugs like Chlorpheniramine Maleate, Chlorzoxazone, Metformin HCl, Potassium Iodate, Magnesium Hydroxide and many more.
Under specialty chemicals company manufactures Guanidine Nitrate, Dimethyl Amine HCl, 2-Ethoxy Benzoic Acid and 3,4,5, Trimethoxy Benzoic Acid.
Intermediate- Company manufactures products such as Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, Cis-bramo benzoate, 3, 4, 5 - Trimethoxy Benzoic Acid, 2-Ethoxy Benzoic Acid and 5-Bromo Phthalide
Milestones
1992- Company started manufacturing of Sodium Citrate and Potassium Iodide. Company developed antibacterial drug, Trimethoprim.
1996- Company commenced manufacturing of 3,4,5 Trimethoxy Benzaldehyde, which is the basic raw material for Trimethoprim. Company was listed on Bombay Stock Exchange (BSE).
2004-Company received ISO 9001:2000 certification.
2006-Company received certificate of suitability (cos) from the European Directorate of Quality Medicine (EDQM).
2007- Company received DMF No 19910 from the FDA for Metformin Hydrochloride.
Future plansAuro Laboratories plans to widen its product portfolio to strengthen its position in the market.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
